Curevac kicks off new research on cancer

Frankfurt Tübingen-based Curevac AG has lagged far behind in cancer research in recent years, as has vaccines. But here, too, the biotechnology company has now embarked on a new endeavor: “Oncology is the area we will be targeting in parallel with vaccines for infectious diseases,” said Franz-Werner Haas, head of the company, in an interview … Read more

Speculation for acquisition in the pharmaceutical industry

Merck & Co. Last but not least, the financial constellation in the pharmaceutical industry speaks of stronger mergers and acquisitions. (Photo: AP) Frankfurt Acquisitions and mergers in the pharmaceutical industry were rather sluggish in the first half of the year. But with speculation about US biotechnology company Seagen, forecasts for a new wave of mergers … Read more

The new magic ball against cancer

Düsseldorf Since the outbreak of the pandemic, about 140,000 people in Germany have died from or with coronavirus and more than 500,000 people are likely to have lost the battle against cancer in the same period. Such data and relationships remind us that the challenges facing medicine in the 21st century still far outweigh the … Read more

German biotechnology companies: development in a difficult environment

in the traces of genes Sample preparation for genetic analysis: German biotechnology companies are in demand by investors. (Photo: IMAGO / Westend61) Frankfurt At first glance, investment in the German biotechnology industry is still high: According to the biotechnology report of the control and consulting company EY, in 2021, 2.4 billion euros were invested. This … Read more

German biotechnology companies: development in a difficult environment

in the traces of genes Sample preparation for genetic analysis: German biotechnology companies are in demand by investors. (Photo: IMAGO / Westend61) Frankfurt At first glance, investment in the German biotechnology industry is still high: According to the biotechnology report of the control and consulting company EY, in 2021, 2.4 billion euros were invested. This … Read more

The cancer specialist receives 60 million euros from investors

The founders of Tubulis, Dominik Schumacher (left) and Jonas Helma-Smets PhD physicists founded their company three years ago. (Photo: Lisa Eiden Photography) Frankfurt Munich Tubulis cancer specialist will receive 60 million euros to further develop his therapeutic approach. The start-up announced on Tuesday that it had successfully closed a B-Series funding round, led by European … Read more